135 related articles for article (PubMed ID: 34242421)
1. Combinatorial treatment for unresectable unicentric Castleman disease.
Mohan M; Meek JC; Meek ME; Broadwater R; Alapat D; van Rhee F
Eur J Haematol; 2021 Oct; 107(4):484-488. PubMed ID: 34242421
[TBL] [Abstract][Full Text] [Related]
2. Unicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
[TBL] [Abstract][Full Text] [Related]
3. A patient with Castleman's disease mimicking acute pancreatitis.
Wu J; Lv L; Wang C
Rev Esp Enferm Dig; 2017 Oct; 109(10):737-738. PubMed ID: 28929773
[TBL] [Abstract][Full Text] [Related]
4. Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
Melikyan AL; Egorova EK; Julhakyan HL; Kovrigina AL; Savchenko VG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S159-65. PubMed ID: 27133959
[TBL] [Abstract][Full Text] [Related]
5. The management of Castleman disease.
Lomas OC; Streetly M; Pratt G; Cavet J; Royston D; Schey S; Ramasamy K;
Br J Haematol; 2021 Nov; 195(3):328-337. PubMed ID: 34340261
[No Abstract] [Full Text] [Related]
6. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.
Zhu SH; Yu YH; Zhang Y; Sun JJ; Han DL; Li J
Med Oncol; 2013 Mar; 30(1):492. PubMed ID: 23400962
[TBL] [Abstract][Full Text] [Related]
8. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and management of Castleman disease.
Soumerai JD; Sohani AR; Abramson JS
Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
[TBL] [Abstract][Full Text] [Related]
10. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.
Bowne WB; Lewis JJ; Filippa DA; Niesvizky R; Brooks AD; Burt ME; Brennan MF
Cancer; 1999 Feb; 85(3):706-17. PubMed ID: 10091744
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Direct Puncture Embolization of Castleman Disease of the Parotid Gland: A Case Report.
Pedicelli A; Trombatore P; Bartolo A; Camilli A; Rossi ED; Scarcia L; Alexandre AM
Curr Oncol; 2024 Apr; 31(4):2047-2056. PubMed ID: 38668054
[TBL] [Abstract][Full Text] [Related]
12. Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report.
Zhuang H; Ma Z; Wu Y; Yin Z; Jian Z; Zhang C; Hou B
Transl Cancer Res; 2020 Apr; 9(4):3030-3033. PubMed ID: 35117662
[TBL] [Abstract][Full Text] [Related]
13. Multicentric Castleman's disease in a renal allograft recipient: a case report and literature review.
Lin J; Yu S; Wang R; Chen J
J Int Med Res; 2020 Feb; 48(2):300060519897481. PubMed ID: 32046545
[TBL] [Abstract][Full Text] [Related]
14. Unicentric Castleman Disease.
Wong RSM
Hematol Oncol Clin North Am; 2018 Feb; 32(1):65-73. PubMed ID: 29157620
[TBL] [Abstract][Full Text] [Related]
15. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Rampotas A; Wilson MR; Lomas O; Denny N; Leary H; Ferguson G; McKay P; Ebsworth T; Miller J; Shah N; Martinez-Calle N; Bishton M; Everden A; Tucker D; El-Hassad E; Hennessy B; Doherty D; Prideaux S; Faryal R; Hayat A; Keohane C; Marr H; Gibb A; Pocock R; Lambert J; Lacey R; Elmusharaf N; Clifford R; Eyre TA
Br J Haematol; 2021 Jul; 194(2):365-377. PubMed ID: 33959947
[TBL] [Abstract][Full Text] [Related]
18. The Role of Radiation Therapy in Unicentric Castleman Disease: A Case Report.
Rodriguez C; Rivera Rubi L; Menjivar O; Suazo J
Cureus; 2023 Nov; 15(11):e49687. PubMed ID: 38161935
[TBL] [Abstract][Full Text] [Related]
19. Multicentric Castleman's disease.
Herrada J; Cabanillas FF
Am J Clin Oncol; 1995 Apr; 18(2):180-3. PubMed ID: 7900713
[No Abstract] [Full Text] [Related]
20. [Efficacy and prognostic analysis of frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone regimens (VR-CAP) for patients with mantle cell lymphoma].
Cao YW; Zheng Z; Xu PP; Cheng S; Wang L; Qian Y; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):415-419. PubMed ID: 34218585
[No Abstract] [Full Text] [Related]
[Next] [New Search]
